Axol Bioscience Secures $2.8M to Expand iPSC Disease Model Platform and US Operations
核心洞察
Axol Bioscience (搜索) raised $2.8 million in funding led by BroadOak Capital Partners (搜索) to accelerate US expansion and enhance its induced pluripotent stem cell (搜索) technology platform.
The investment will support development of enhanced neuroscience, ophthalmology, and cardiovascular disease models while scaling cell manufacturing capacity at the company's Edinburgh facility.
The funding follows strong commercial momentum with 45% revenue growth in 2025 and 36% in 2024, positioning Axol as a leader in physiologically relevant iPSC-derived models for neurodegenerative disorders (搜索).
Axol Bioscience (搜索) Ltd., a leading provider of induced pluripotent stem cell (搜索) (iPSC) technologies for drug discovery and disease research, has secured $2.8 million (£2.1 million) in funding to accelerate its expansion into the US market and enhance its disease modeling capabilities. The investment was led by US life sciences specialist BroadOak Capital Partners (搜索), with participation from the company's founding investor, the Roslin Foundation (搜索).
Strategic Investment to Drive Growth
The funding will support multiple strategic initiatives as Axol enters its next phase of growth. The investment will enable the expansion of US operations and commercial presence, addressing increasing global demand for human-relevant in vitro disease models. Additionally, the funding will facilitate the development of enhanced neuroscience, ophthalmology, and cardiovascular disease models, while supporting cell manufacturing scale-up at the company's Roslin Innovation Centre base in Edinburgh.
"We're proud to partner with BroadOak, a global leader in life sciences investing. Their expertise and support, alongside our long-term partner Roslin Foundation (搜索), reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally," said Liam Taylor, CEO of Axol Bioscience (搜索).
Strong Commercial Performance Drives Investment
The funding follows a period of exceptional commercial growth for Axol Bioscience (搜索). The company achieved 45% revenue growth in 2025 and 36% in 2024, demonstrating sustained double-digit expansion. This strong performance has been driven by increasing demand for the company's physiologically relevant iPSC-derived disease models across pharmaceutical, biotech, contract research organizations (CROs), and academic institutions worldwide.
"Following Axol's 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand," added Oliver Richardson, CFO of Axol Bioscience (搜索).
Leadership in Neurodegenerative Disease Models
Axol Bioscience (搜索) has established itself as a leader in providing physiologically relevant iPSC-derived models for neurodegenerative disorders (搜索), including Huntington's disease (搜索) and sporadic amyotrophic lateral sclerosis (搜索) (ALS/MND). These models address significant unmet needs in neurodegenerative disease research by offering more human-relevant alternatives to traditional research models.
The company develops and supplies high-quality functional iPSC-derived cells, reagents, and specialist services to support drug discovery and disease research efforts globally. This positioning has enabled Axol to strengthen relationships with global pharmaceutical partners while advancing its presence in key markets.
Regulatory Tailwinds Support Market Expansion
The investment comes at a time when global regulators are actively promoting the adoption of cell-based models, creating favorable conditions for companies like Axol. "Axol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models. We are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth," said Daniel Friedman, Managing Director at BroadOak Capital Partners (搜索).
Manufacturing and Quality System Investments
Over the past year, Axol has continued to invest in manufacturing and quality systems at its Edinburgh facility, supporting its ability to meet growing demand for its products and services. The company has also expanded its portfolio of physiologically relevant iPSC-derived disease models, further reinforcing its position as a trusted supplier of human-relevant in vitro models to the life sciences industry.
The strategic momentum includes strengthened relationships with global pharmaceutical partners and advanced US market presence, positioning the company for continued growth in the expanding market for alternative research models.